83 related articles for article (PubMed ID: 8852497)
1. Verapamil deleterious effects in chronic renal failure.
Váquez C; Huelmos A; Alegría E; Errasti P; Purroy A
Nephron; 1996; 72(3):461-4. PubMed ID: 8852497
[TBL] [Abstract][Full Text] [Related]
2. Junctional bradycardia with verapamil in renal failure--care required even with mild hyperkalaemia.
Hegazi MO; Aldabie G; Al-Mutairi S; El Sayed A
J Clin Pharm Ther; 2012 Dec; 37(6):726-8. PubMed ID: 22568727
[TBL] [Abstract][Full Text] [Related]
3. Acute toxic effects of sustained-release verapamil in chronic renal failure.
Pritza DR; Bierman MH; Hammeke MD
Arch Intern Med; 1991 Oct; 151(10):2081-4. PubMed ID: 1843183
[TBL] [Abstract][Full Text] [Related]
4. Long term effects of sustained release verapamil on the renal and systemic haemodynamic parameters in hypertensive patients with mild to severe chronic renal failure.
Schohn DC; Jahn HA; Maareck M
Drugs; 1993; 46 Suppl 2():113-9; discussion 119-20. PubMed ID: 7512464
[TBL] [Abstract][Full Text] [Related]
5. [The effects of slow-release verapamil in relation to plasma concentration in aged hypertensives. A study with continuous monitoring of arterial pressure and electrocardiogram].
Canonico V; Bonaduce D; De Caprio L; Nicolino A; Forgione L; Petretta M; Rengo F
G Ital Cardiol; 1990 Oct; 20(10):924-32. PubMed ID: 2090531
[TBL] [Abstract][Full Text] [Related]
6. Verapamil sustained-release in renal parenchymal hypertension: effect on blood pressure, kidney function, angiotensin II, aldosterone, arginine vasopressin, atrial natriuretic peptide, and lipoproteins.
Eiskjaer H; Pedersen EB; Rasmussen LM; Jespersen B
J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S17-22. PubMed ID: 2475677
[TBL] [Abstract][Full Text] [Related]
7. Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day).
Lanteri-Minet M; Silhol F; Piano V; Donnet A
J Headache Pain; 2011 Apr; 12(2):173-6. PubMed ID: 21258839
[TBL] [Abstract][Full Text] [Related]
8. Verapamil reverses myocardial no-reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction.
Fu Q; Lu W; Huang YJ; Wu Q; Wang LG; Wang HB; Jiang SZ; Wang YJ
Cell Biochem Biophys; 2013; 67(3):911-4. PubMed ID: 23559273
[TBL] [Abstract][Full Text] [Related]
9. Verapamil in antihypertensive treatment of patients on renal replacement therapy--clinical implications and pharmacokinetics.
Beyerlein C; Csaszar G; Hollmann M; Schumacher A
Eur J Clin Pharmacol; 1990; 39 Suppl 1():S35-7. PubMed ID: 2261942
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of verapamil, flecainide and propafenone for the acute conversion of atrial fibrillation to sinus rhythm.
Kondili A; Kastrati A; Popa Y
Wien Klin Wochenschr; 1990 Sep; 102(17):510-3. PubMed ID: 2124756
[TBL] [Abstract][Full Text] [Related]
11. [Effects of sustained-release verapamil on hemodynamics and renal function of patients with moderate to severe chronic renal failure].
Schohn D; Maarek M; Jahn H
Presse Med; 1993 Nov; 22(37):1856-60. PubMed ID: 8115329
[TBL] [Abstract][Full Text] [Related]
12. [The toxicity of slow-release verapamil and chronic kidney disease].
Huelmos A; Alegría E; Vázquez C
Rev Esp Cardiol; 1994 Nov; 47(11):780. PubMed ID: 7800911
[No Abstract] [Full Text] [Related]
13. [Severe intoxication with verapamil].
González-Castro A; Suberviola Cañas B; Burón Mediavilla FJ; San José JM; González C; Vázquez de Prada JA
Med Intensiva; 2008 Apr; 32(3):151-2. PubMed ID: 18381021
[No Abstract] [Full Text] [Related]
14. 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation.
Mølgaard H; Bjerregaard P; Jørgensen HS; Klitgaard NA
Eur J Clin Pharmacol; 1987; 33(5):447-53. PubMed ID: 3428338
[TBL] [Abstract][Full Text] [Related]
15. A new sustained-release formulation of verapamil in the treatment of hypertension.
Midtbo KA; Hals O; Lauve O
J Clin Hypertens; 1986 Sep; 2(3 Suppl):125S-132S. PubMed ID: 3540222
[TBL] [Abstract][Full Text] [Related]
16. [Conversion rate and prevention of recurrence of paroxysmal and sustained atrial fibrillation or atrial flutter with verapamil/quinidine].
Trappe HJ; Pfitzner P
Med Klin (Munich); 1996 Oct; 91(10):617-25. PubMed ID: 9019638
[TBL] [Abstract][Full Text] [Related]
17. [Delayed-release verapamil hydrochloride in chronic atrial fibrillation. Reducing the heart rate].
Gonska BD; Wiedey KD
Fortschr Med; 1990 Sep; 108(27):521-4. PubMed ID: 2227752
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension.
Frishman WH; Eisen G; Charlap S; Strom JA
J Clin Hypertens; 1987 Dec; 3(4):605-9. PubMed ID: 3134517
[TBL] [Abstract][Full Text] [Related]
19. Noctural dosing of a novel delivery system of verapamil for systemic hypertension.
White WB
Am J Cardiol; 1996 May; 77(11):1030. PubMed ID: 8644635
[No Abstract] [Full Text] [Related]
20. Verapamil versus nifedipine in slow-release preparations for the treatment of mild to moderate hypertension.
Shamiss A; Meisel S; Nussinovitch N; Rosenthal T
J Hum Hypertens; 1990 Aug; 4(4):465-8. PubMed ID: 2258895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
